Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07283939 · ClinicalTrials.gov registry record · NA
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
A NA study, sponsored by Alliance for Clinical Trials in Oncology.
- Recruiting
- Registry status
- NA
- Development phase
- 420
- Enrollment target
NCT07283939: Recruiting NA study, sponsored by Alliance for Clinical Trials in Oncology.
NCT07283939 is a NA study that is actively recruiting participants, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 420 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (70% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07283939, a NA study, is actively recruiting participants, sponsored by Alliance for Clinical Trials in Oncology.
- RECRUITING
- Registry status
- NA
- Development phase
- 420 participants
- Enrollment target
Study Summary
This study seeks to learn whether using the PAGODA algorithm to guide chemotherapy dosing will lower the chance of unplanned delays during chemotherapy for cancer in the gastrointestinal system compared to usual care.
Primary Outcome
Will employ a generalized linear mixed effects model with logit link function, with a random patient effect to account for clustering of cycles within patients. Will test if additional random effects are needed (e.g., provider or clinic level). Statistical significance will be assessed at the 5% level. Delays will be assessed over cycles 2 through 7, and a delay will be defined as an interval of \> 18 days since day 1 of the previous cycle. An unplanned delay will be defined as any delay that wa
Interventions
- DRUG Fluorouracil
- DRUG Oxaliplatin
- DRUG Folinic Acid
- OTHER PAGODA algorithm
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 420 participants |
| Start Date | 2026-02-13 |
| Est. Completion | 2030-05-02 |
| Phase | NA |
What NCT07283939 shows while recruiting
NCT07283939 is an interventional study that assigns participants to a tested intervention. The registered 420 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (70% lower).
The record links to 0 conditions, and to 4 interventions - of which Fluorouracil is the first listed.
NCT07283939 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07283939 about?
NCT07283939 is a clinical study titled "Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays". This study seeks to learn whether using the PAGODA algorithm to guide chemotherapy dosing will lower the chance of unplanned delays during chemotherapy for cancer in the gastrointestinal system compared to usual care.
What is the current status of trial NCT07283939?
This trial is currently recruiting. It is a NA study. The enrollment target is 420 participants. The study started on 2026-02-13. Estimated completion is 2030-05-02.
What interventions are being tested in trial NCT07283939?
The interventions under investigation include: Fluorouracil (DRUG), Oxaliplatin (DRUG), Folinic Acid (DRUG), PAGODA algorithm (OTHER).
Who is sponsoring clinical trial NCT07283939?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07283939's enrollment target sits among peer trials
420 239th of 2000 higher than 1,761 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01790152 · 420 participants
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- NCT02701244 · 420 participants
A Registry Study of Breast Microseed Treatment
- NCT02966665 · 420 participants · Phase 1
: Vascular Function in Health and Disease
- NCT04149743 · 420 participants · NA
HEMOTAG® Assessment for Short-term Outcomes of Heart Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI